Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,895,313
  • Shares Outstanding, K 285,579
  • Annual Sales, $ 1,830 M
  • Annual Income, $ 207,770 K
  • EBIT $ 523 M
  • EBITDA $ 549 M
  • 60-Month Beta 0.51
  • Price/Sales 5.37
  • Price/Cash Flow 44.83
  • Price/Book 4.33

Options Overview Details

View History
  • Implied Volatility 31.61% ( -1.68%)
  • Historical Volatility 44.69%
  • IV Percentile 9%
  • IV Rank 24.40%
  • IV High 72.42% on 08/05/24
  • IV Low 18.44% on 11/08/24
  • Put/Call Vol Ratio 0.57
  • Today's Volume 1,173
  • Volume Avg (30-Day) 2,404
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 43,458
  • Open Int (30-Day) 62,541

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.40
  • Number of Estimates 10
  • High Estimate 0.52
  • Low Estimate 0.19
  • Prior Year 0.27
  • Growth Rate Est. (year over year) +48.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.86 +24.37%
on 10/25/24
36.60 -5.33%
on 11/08/24
+5.75 (+19.90%)
since 10/18/24
3-Month
25.12 +37.94%
on 09/09/24
36.60 -5.33%
on 11/08/24
+8.17 (+30.85%)
since 08/20/24
52-Week
19.20 +80.47%
on 01/08/24
36.60 -5.33%
on 11/08/24
+13.72 (+65.55%)
since 11/20/23

Most Recent Stories

More News
3 Magnificent Stocks Under $100 to Buy in November

The price could be right for these stocks.

AZN : 63.78 (+0.92%)
SMMT : 18.90 (+1.50%)
MRK : 97.61 (+0.17%)
EXEL : 34.65 (+0.70%)
Exelixis (EXEL) Q3 2024 Earnings Call Transcript

EXEL earnings call for the period ending September 30, 2024.

EXEL : 34.65 (+0.70%)
Exelixis: Q3 Earnings Snapshot

Exelixis: Q3 Earnings Snapshot

EXEL : 34.65 (+0.70%)
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma

For Immediate ReleaseChicago, IL – October 25, 2024 – Today, Zacks Equity Research discusses Exelixis, Inc, EXEL, Blueprint Medicines BPMC, CRISPR Therapeutics CRSP, Amicus Therapeutics FOLD and Verona...

FOLD : 9.59 (+0.74%)
CRSP : 47.59 (+0.70%)
VRNA : 39.90 (+2.70%)
EXEL : 34.65 (+0.70%)
BPMC : 94.81 (+0.22%)
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major...

FOLD : 9.59 (+0.74%)
CRSP : 47.59 (+0.70%)
VRNA : 39.90 (+2.70%)
EXEL : 34.65 (+0.70%)
BPMC : 94.81 (+0.22%)
1 No-Brainer Stock to Buy With $40

The midcap biotech just became an even better buy.

EXEL : 34.65 (+0.70%)
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More

Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.Here's...

JAZZ : 122.00 (+2.31%)
EXEL : 34.65 (+0.70%)
NVAX : 7.98 (-0.99%)
VNDA : 4.90 (unch)
2 Growth Stocks to Buy With Less Than $100

No need to break the bank to get in on these likely long-term winners.

SHOP : 104.40 (+0.44%)
EXEL : 34.65 (+0.70%)
Investors Watch Key Players in Oncology as Cancer Cases Set to Skyrocket

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – The surge in...

ONCY : 1.0300 (+3.15%)
BGNE : 194.26 (+3.46%)
EXEL : 34.65 (+0.70%)
ABBV : 168.17 (+0.24%)
ONC.TO : 1.40 (-5.41%)
AMGN : 288.77 (+0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 35.45
2nd Resistance Point 35.13
1st Resistance Point 34.89
Last Price 34.65
1st Support Level 34.33
2nd Support Level 34.01
3rd Support Level 33.77

See More

52-Week High 36.60
Last Price 34.65
Fibonacci 61.8% 29.95
Fibonacci 50% 27.90
Fibonacci 38.2% 25.85
52-Week Low 19.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar